<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01255046</url>
  </required_header>
  <id_info>
    <org_study_id>MCCD09009A</org_study_id>
    <nct_id>NCT01255046</nct_id>
  </id_info>
  <brief_title>Study of STA-1 as an Add-on Treatment to Donepezil</brief_title>
  <official_title>A Phase II Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of STA-1 as an Add-on Treatment to Donepezil in Patients With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinphar Pharmaceutical Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinphar Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of STA-1 vs placebo as an
      add-on treatment to donepezil in patients with mild to moderate Alzheimer's Disease (AD).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in ADAS-cog at Week 72</measure>
    <time_frame>from baselline (Visit 2) to week 72 (Visit 9)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Mini-Mental State Examination Scale Score (MMSE) at 72 week</measure>
    <time_frame>baseline (V2) to week 72 (Visit 8)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Donepezil plus STA-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil,</intervention_name>
    <description>10mg/tab, 1 tab/day for 72 weeks</description>
    <arm_group_label>Donepezil plus STA-1</arm_group_label>
    <arm_group_label>Donepezil plus placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STA-1</intervention_name>
    <description>300mg/tab, 2 tab/tid for 72 weeks</description>
    <arm_group_label>Donepezil plus STA-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2 tab/tid for 72 weeks</description>
    <arm_group_label>Donepezil plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient aged â‰¥ 50 years;

          -  Probable Alzheimer's disease diagnosed by the National Institute of Neurological and
             Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders
             Association (NINCDS-ADRDA) criteria;

          -  MMSE score between 10-26, inclusive;

          -  Patient has been treated with donepezil 10 mg per day for at least 3 months prior to
             screening;

          -  Patient able to participate in all study evaluations and ingest oral medication as
             indicated;

          -  Patient has a responsible caregiver who will accompany the patient to all clinic
             visits during the study;

          -  Patient and the responsible caregiver have provided written informed consent before
             undergoing any study procedures.

        Exclusion Criteria:

          -  Brain image (computed tomography (CT) scan or Magnetic Resonance Imaging (MRI) done
             within past 12 months prior to the study) and laboratory tests to exclude secondary
             dementia or non-Alzheimer's dementia;

          -  Patient with significant clinically central nervous system illness other than AD (e.g.
             Parkinson's disease, Human Immunodeficiency Virus (HIV) induced dementia, Hachinski
             Ischaemic Score (HIS) &gt;4) or dementia complicated by other organic disease or
             delirium;

          -  Patient with a severe or uncontrolled Diagnostic and Statistical Manual of Mental
             Disorders (DSM-IV) Axis I disorder other than Alzheimer's disease, including amnestic
             disorders, schizophrenia or schizoaffective disorder, bipolar disorder, current major
             depressive episode, psychosis, panic, or post-traumatic stress disorder;

          -  Patient suffering from cerebral disturbances following a stroke or a cerebral trauma
             (if the event occurred within the last 6 months);

          -  Patient with a history of hypersensitivity to study drugs;

          -  Patient who has a history or evidence of a medical condition that would expose them to
             an undue risk of a significant adverse event or interfere with assessments of safety
             or efficacy during the course of the trial, including but not limited to hepatic,
             renal, respiratory, cardiovascular, endocrine (e.g., Addison's Disease), immune,
             neurologic, or hematologic disease as determined by the clinical judgment of the
             investigator;

          -  Participation in any research study within the last 30 days;

          -  Patient with significant alcohol or drug abuse as judged by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giia-Sheun Peng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tri-Service General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2010</study_first_submitted>
  <study_first_submitted_qc>December 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2010</study_first_posted>
  <last_update_submitted>August 19, 2014</last_update_submitted>
  <last_update_submitted_qc>August 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

